Literature DB >> 18326303

[Analysis of application form for Parkinson's disease provided by the specific diseases treatment research program of Ministry of Health, Labour and Welfare of Japan].

Akira Taniguchi1, Yugo Narita, Yutaka Naito, Shigeki Kuzuhara.   

Abstract

The Ministry of Health, Labour and Welfare (MHLW) of Japan has funded special research programs to investigate etiology and treatment of intractable neurodegenerative diseases. Individual health-care expenditures for registered patients with Parkinson's disease (PD) (Hoehn and Yahr Stage 3-5) have been evaluated by the government. The total number of patients registered with a diagnosis of degenerative parkinsonism including PD, progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) was 75,026 in 2004. We analyzed the data from a survey of application forms completed by 23,058 PD patients, which had been entered into the MHLW's computer. The male to female ratio was 1: 1.47, and the mean ages of all patients at registration and at onset were 71.3 years and 62.7 years, respectively. Incidence of young-onset Parkinson's disease was 2.7% of all PD patients. The percentage of PD patients at Hoehn and Yahr Stage 3 was 48.8%, at Stage 4, 23.1%, and at Stage 5, 25.2%. About 60% of patients resided at home, whereas 20% were admitted into the hospital and 20% into a nursing home. The percentages of patients with diurnal fluctuations, dyskinesia and psychotic symptoms were 37.3%, 16.8% and 18.4%, respectively. Ages of patients at registration and at disease onset who presented with diurnal fluctuations and dyskinesia were typically younger and the duration of disease was longer than for those presented without them (p < 0.0001). Patients with psychotic symptoms were older and the duration of disease was longer than those without them (p < 0.0001). Ages of patients receiving ablative surgery were younger than those who received deep brain stimulation (DBS) (57.4 versus 63.1 years, p < 0.01). Approximately 70% of all the patients who underwent stereotactic surgeries were treated within 10 years from onset. The percentage of patients with feeding tube was 6.6%, and the age at registration was older (75.6 versus 71.0 years, p < 0.0001) and duration of disease was longer (11.0 versus 8.4 years, p < 0.0001) in patients with feeding tube than in patients with oral feeding. This is the first analysis of results from the survey of questionnaire for PD provided by MHLW.

Entities:  

Mesh:

Year:  2008        PMID: 18326303     DOI: 10.5692/clinicalneurol.48.106

Source DB:  PubMed          Journal:  Rinsho Shinkeigaku        ISSN: 0009-918X


  7 in total

1.  Real-world pharmacological treatment patterns of patients with young-onset Parkinson's disease in Japan: a medical claims database analysis.

Authors:  Sachiko Kasamo; Masato Takeuchi; Masashi Ikuno; Yohei Kawasaki; Shiro Tanaka; Ryosuke Takahashi; Koji Kawakami
Journal:  J Neurol       Date:  2019-05-10       Impact factor: 4.849

2.  Prescribing pattern of anti-Parkinson drugs in Japan: a trend analysis from 2005 to 2010.

Authors:  Sachiko Nakaoka; Tatsuro Ishizaki; Hisashi Urushihara; Toshihiko Satoh; Shunya Ikeda; Mitsutoshi Yamamoto; Takeo Nakayama
Journal:  PLoS One       Date:  2014-06-06       Impact factor: 3.240

3.  Treatment Satisfaction and Its Influencing Factors in Parkinson's Disease: A Web-Based Survey of Patients and Physicians in Clinical Practice in Japan.

Authors:  Masahiro Nomoto; Ayako Hayashi; Hiroyuki Ida; Masaki Arai
Journal:  Parkinsons Dis       Date:  2022-02-23

4.  Baseline Plasma C-Reactive Protein Concentrations and Motor Prognosis in Parkinson Disease.

Authors:  Atsushi Umemura; Tomoko Oeda; Kenji Yamamoto; Satoshi Tomita; Masayuki Kohsaka; Kwiyoung Park; Hiroshi Sugiyama; Hideyuki Sawada
Journal:  PLoS One       Date:  2015-08-26       Impact factor: 3.240

5.  A Cross-Sectional Study on Socioeconomic Systems Supporting Outpatients With Parkinson's Disease in Japan.

Authors:  Aiko Matsushima; Akihisa Matsumoto; Fumio Moriwaka; Sanae Honma; Kazunori Itoh; Keiko Yamada; Shun Shimohama; Hirofumi Ohnishi; Junichi Matsushima; Mitsuru Mori
Journal:  J Epidemiol       Date:  2015-12-05       Impact factor: 3.211

6.  Safety and efficacy of levodopa-carbidopa intestinal gel: results from an open-label extension study in Japanese, Korean and Taiwanese patients with advanced Parkinson's disease.

Authors:  Miho Murata; Masahito Mihara; Kazuko Hasegawa; Beomseok Jeon; Chon-Haw Tsai; Noriko Nishikawa; Tomoko Oeda; Masayuki Yokoyama; Weining Z Robieson; Krai Chatamra; Maurizio F Facheris; Janet Benesh
Journal:  Ther Adv Neurol Disord       Date:  2018-02-26       Impact factor: 6.570

7.  Efficacy and safety of levodopa-carbidopa intestinal gel from a study in Japanese, Taiwanese, and Korean advanced Parkinson's disease patients.

Authors:  Miho Murata; Masahito Mihara; Kazuko Hasegawa; Beomseok Jeon; Chon-Haw Tsai; Noriko Nishikawa; Tomoko Oeda; Masayuki Yokoyama; Weining Z Robieson; Davis Ryman; Susan Eaton; Krai Chatamra; Janet Benesh
Journal:  NPJ Parkinsons Dis       Date:  2016-11-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.